<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170153</url>
  </required_header>
  <id_info>
    <org_study_id>MS201924_0001</org_study_id>
    <secondary_id>2019-002203-18</secondary_id>
    <nct_id>NCT04170153</nct_id>
  </id_info>
  <brief_title>M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors</brief_title>
  <official_title>An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase I, first-in-human (FIH) multicenter, clinical study conducted in
      multiple parts to establish the safety, tolerability and Pharmacokinetic/Pharmacodynamic
      (PK/PD) profile (with and without food) of M1774.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2019</start_date>
  <completion_date type="Anticipated">September 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open-Label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A1: Occurrence of Dose-Limiting Toxicities (DLTs) During the DLT Observation Period</measure>
    <time_frame>Day 1 to Day 21 of Cycle 1 (Each Cycle is of 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A1 and A3: Occurrence of Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (AEs) and Death According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0</measure>
    <time_frame>Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A1 and A3: Number of Participants With Grade 3 or Higher Laboratory Findings According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0</measure>
    <time_frame>Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A1 and A3: Number of Participants With Abnormalities in Vital Signs</measure>
    <time_frame>Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A1 and A3: Number of Participants With Clinical Significant Abnormalities in Electrocardiogram(ECG) Findings</measure>
    <time_frame>Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A2: Area Under the Plasma Concentration Curve From Time Zero to 24 Hours Post Dose (AUC 0-24h) of M1774</measure>
    <time_frame>Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A2: Maximum Observed Plasma Concentration (Cmax) of M1774</measure>
    <time_frame>Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A2: Relative Bioavailability Based on Area Under the Plasma Concentration Curve (Frel[AUC]) of M1774 Under Fed Condition as Compared to Fasting Condition</measure>
    <time_frame>Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A2: Relative Bioavailability Based on Maximum Observed Plasma Concentration (Frel[Cmax]) of M1774 Under Fed Condition as Compared to Fasting Condition</measure>
    <time_frame>Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A3: Objective Response as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1</measure>
    <time_frame>Baseline up to 2.2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Maximum Observed Plasma Concentration (Cmax) of M1774</measure>
    <time_frame>Cycle 1 Day 1 and Day 8: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Time to Reach Maximum Plasma Concentration (tmax) of M1774</measure>
    <time_frame>Cycle 1 Day 1 and Day 8: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Area Under the Plasma Concentration Curve From Time Zero to 24 Hours Post Dose AUC(0-24h) of M1774</measure>
    <time_frame>Cycle 1 Day 1 and Day 8: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Area Under Plasma Concentration-Time Curve Within One Dosing Interval (AUC0-tau) of M1774</measure>
    <time_frame>Cycle 1 Day 1 and Day 8: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of M1774</measure>
    <time_frame>Cycle 1 Day 1 and Day 8: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Apparent Terminal Half-life (t1/2) of M1774</measure>
    <time_frame>Cycle 1 Day 1 and Day 8: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Apparent Total Body Clearance From Plasma (CL/f) of M1774</measure>
    <time_frame>Cycle 1 Day 1 and Day 8: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Apparent Clearance Body Clearance at Steady State Following Extravascular Administration (CLss/F) of M1774</measure>
    <time_frame>Cycle 1 Day 1 and Day 8: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Apparent Volume of Distribution During Terminal Phase Following Extravascular Administration (Vz/F) of M1774</measure>
    <time_frame>Cycle 1 Day 1 and Day 8: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Accumulation Ratio for Area Under the Plasma Concentration Concentration-Time Curve (Racc[AUC]) of M1774</measure>
    <time_frame>Cycle 1 Day 1 and Day 8: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Accumulation Ratio of Maximum Observed Plasma Concentration (Racc[Cmax]) of M1774</measure>
    <time_frame>Cycle 1 Day 1 and Day 8: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Dose Normalized Area Under Concentration-Time Curve Within One Dosing Interval (AUC0-tau/Dose) of M1774</measure>
    <time_frame>Cycle 1 Day 1 and Day 8: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Dose Normalized Area Under Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24h/Dose) Post-dose of M1774</measure>
    <time_frame>Cycle 1 Day 1 and Day 8: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Dose Normalized Area Under Concentration-Time Curve From Time Zero (dosing time) Extrapolated to Infinity (AUC0-inf/Dose) of M1774</measure>
    <time_frame>Cycle 1 Day 1 and Day 8: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Dose Normalized Maximum Observed Plasma Concentration (Cmax/Dose) of M1774</measure>
    <time_frame>Cycle 1 Day 1 and Day 8: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Area Under Concentration From Time tlast Extrapolated to Infinity (AUCextra%) of M1774</measure>
    <time_frame>Cycle 1 Day 1 and Day 8: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A1 and A3: Number of Participants With Corrected QT (QTc) Interval</measure>
    <time_frame>Baseline up to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Occurrence of Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (AEs) and Death According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0</measure>
    <time_frame>Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Number of Participants With Grade 3 or Higher Laboratory Findings According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0</measure>
    <time_frame>Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Number of Participants With Abnormalities in Vital Signs</measure>
    <time_frame>Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Number of Participants With Clinical Significant Abnormalities in Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Time to Reach Maximum Plasma Concentration (tmax) Under Fed/Fasted Ratio of M1774</measure>
    <time_frame>Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Area Under Plasma Concentration-Time Curve Within One Dosing Interval (AUC0-tau) of M1774</measure>
    <time_frame>Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of M1774</measure>
    <time_frame>Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Apparent Terminal Half-life (t1/2) of M1774</measure>
    <time_frame>Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Apparent Total Body Clearance From Plasma (CL/f) of M1774</measure>
    <time_frame>Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Apparent Volume of Distribution During Terminal Phase Following Extravascular Administration (Vz/F) of M1774</measure>
    <time_frame>Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Dose Normalized Area Under Concentration Time Curve Within One Dosing Interval (AUC0-tau/Dose) of M1774</measure>
    <time_frame>Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Dose Normalized Area Under Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24h/Dose) Post dose of M1774</measure>
    <time_frame>Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Dose Normalized Area Under Concentration-Time Curve From Time Zero (dosing time) Extrapolated to Infinity (AUC0-inf/Dose) of M1774</measure>
    <time_frame>Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Dose Normalized Maximum Observed Plasma Concentration (Cmax/Dose) of M1774</measure>
    <time_frame>Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Area Under Concentration From Time tlast Extrapolated to Infinity (AUCextra%) of M1774</measure>
    <time_frame>Cycle 1 Day -7 and Day 1: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Cumulative Amount Excreted From Time Zero (dosing time) to Infinity (Ae0-inf) of M1774</measure>
    <time_frame>Cycle 1 Day -7: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Cumulative Amount Excreted From Time Zero to Time After Dosing (Ae0-t) of M1774</measure>
    <time_frame>Cycle 1 Day -7: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Cumulative Percentage of Dose Excreted From Time Zero to Time After Dosing (Ae0-t%) of M1774</measure>
    <time_frame>Cycle 1 Day -7: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Renal Clearance (CLr) of M1774</measure>
    <time_frame>Cycle 1 Day -7: Pre-dose up to 24 hours post-dose (Each Cycle is of 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A2: Number of Participants With Corrected QT (QTc) Interval</measure>
    <time_frame>Baseline up to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A3: Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1</measure>
    <time_frame>Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A3: Number of Participants With Clinical Benefit According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1</measure>
    <time_frame>Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years</time_frame>
    <description>Participants with a clinical benefit, defined as an objective response or stable disease for at least 6 months, as determined by the Investigator through the use of RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A3: Progression-Free Survival (PFS) as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1</measure>
    <time_frame>Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A3: Overall Survival (OS) According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1</measure>
    <time_frame>Baseline up to 30 days after the last dose of study treatment, assessed up to approximately 2.2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Metastatic or Locally Advanced Unresectable Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part A1: Monotherapy Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive M1774 once daily under fasting condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A2 - Preliminary Food Effect Assessment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the food effect assessment will receive M1774 at the dose and schedule determined as recommended dose for expansion (RDE) in Part A1. A single dose of M1774 will be administered on Day -7 under a fed (high-fat meal) or fasted condition, followed by a 1-week washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A3 - Monotherapy Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After completion of the scheduled food effect assessments, participants will follow the same schedule as participants in Part A1. Participants will be administered M1774 at a dose and schedule determined as RDE in Part A1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M1774</intervention_name>
    <description>M1774 will be administered orally throughout the study.</description>
    <arm_group_label>Part A1: Monotherapy Dose Escalation</arm_group_label>
    <arm_group_label>Part A2 - Preliminary Food Effect Assessment</arm_group_label>
    <arm_group_label>Part A3 - Monotherapy Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to
             (&lt;=) 1

          -  Have clinically controlled brain metastases, which is defined as individuals with
             central nervous system metastases that have been treated for, are asymptomatic, and
             have discontinued steroids (for the treatment of brain metastases) for greater than
             (&gt;) 28 days may be enrolled

          -  Participants with meningeal carcinomatosis are excluded

          -  In Part A3, measurable disease according to Response Evaluation Criteria in Solid
             Tumors (RECIST) Version 1.1

          -  Contraceptive use by males or females will be consistent with local regulations on
             contraception methods for those participating in clinical studies

          -  Female participants are not pregnant or breastfeeding

          -  Not a women of childbearing potential (WOCBP)

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Continuance of toxicities due to prior anticancer therapies (example, radiotherapy,
             chemotherapy, immunotherapies, et cetera [etc]) that do not recover to &lt;= Grade 1

          -  Unstable angina, myocardial infarction, congestive heart failure &gt;= II) or a coronary
             revascularization procedure within 180 days of study entry. Calculated QTc average
             (using the Fridericia correction calculation) of &gt; 450 msec for males and &gt; 470 msec
             for females

          -  Active fungal, bacterial and/or viral infection. Individuals with known human
             immunodeficiency virus and/or viral hepatitis (B and/or C) are excluded. However,
             individual with hepatitis C treated with curative therapy are not considered actively
             infected

          -  Treatment with live or live attenuated vaccine within 30 days of dosing

          -  Any other clinical condition or uncontrolled concurrent illness which in the
             Investigator's opinion would not make the participant a good candidate for the
             clinical study

          -  Prohibited concomitant medication, as per Protocol

          -  Another investigational drug within 28 days or 5 half-lives, whichever is shorter,
             prior to start of administration of study intervention

          -  No prior Ataxia telangiectasia mutated and Rad3-related (ATR) inhibitor and/or CHK1
             inhibitor

          -  Participants who cannot comply with restrictions for medications or food

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
    <email>eMediUSA@emdserono.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics - Partner</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>tyap@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Yap</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>atolcher@nextoncology.com</email>
    </contact>
    <investigator>
      <last_name>Anthony W Tolcher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Care - Sir Bobby Robson Cancer Trials Research Centre</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ruth.plummer@newcastle.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Elizabeth R Plummer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Dept of Oncology</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>johann.debono@icr.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Johann S De Bono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS201924_0001</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>M1774</keyword>
  <keyword>ATR inhibitor</keyword>
  <keyword>Metastatic or Locally Advanced Unresectable Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

